Treatment of Basal Cell Carcinoma on Face by Wide Excision in a Community Hospital
Keywords:
skin cancer, basal cell carcinoma, surgeryAbstract
Basal cell carcinoma is the most common human skin malignancy. In 2009, the number of new cases diagnosed in the United States was estimated to be 900,000; 550,000 in men and 350,000 in women. According to Thai National Cancer Institute report Volume X 2016–2018, the age standardized incidence rates (ASR) of skin cancer in male were 4 per 100,000 and 4.3 per 100,000 in female. If the patients receive early treatment, it will be a good prognosis for cure rate and decrease the risk of functional and cosmetic loss. This study reported a case of a male patient aged 86 years with nodular-type basal cell carcinoma, 1.5 cm in diameter on left lower cheek. The patient was treated by surgery to remove all of the cancer and some of the healthy tissue 1 cm around it. Six months after surgery, the patient was still good in cosmetic condition and function of face without recurrence of the tumor and complication.
References
Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.
Rigel DS, Friedman RJ, Kopf AW. Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol. 1996;35(6):1012–3.
Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019;33(1):13–24.
Kauvar ANB, Cronin T Jr, Roenigk R, et al. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(5):550–571.
Medical digital division, National Cancer Institute. Cancer In Thailand Vol.X, 2016 – 2018. Bangkok :National cancer institute; 2012:40–43.
Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–7.
Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. Arch Dermatol. 1995;131(2):157–63.
Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For the Skin Cancer Prevention Study Group. J Natl Cancer Inst. 1996;88(24):1848–53.
Martin H, Strong E, Spiro RH. Radiation-induced skin cancer of the head and neck. Cancer. 1970;25(1):61–71.
Pack GT, Davis J. Radiation cancer of the skin. Radiology. 1965;84:436–42.
Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–60.
Lange E, Blizzard L, Venn A, et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology. 2016;55(9):1594–600.
Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw. 2010;8(8):836–64.
Bath-Hextall F, Bong J, Perkins W, et al. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705.
Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008 ;9(12):1149–56.
Fields RC, Fleming MD, Gastman B, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Melanoma- Version 2.[internet] 2018. [cited 2022 August 19]; Available from: URL: https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf
Codazzi D, Van Der Velden J, Carminati M, et al. Positive compared with negative margins in a single-centre retrospective study on 3957 consecutive excisions of basal cell carcinomas. Associated risk factors and preferred surgical management. J Plast Surg Hand Surg. 2014;48(1):38–43.
Sherry KR, Reid LA, Wilmshurst AD. A five year review of basal cell carcinoma excisions. J Plast Reconstr Aesthet Surg. 2010;63(9):1485–9.
Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123(3):340–4.
Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol. 2006;54(6):1039–45.
Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15(4):424–31.
Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol. 1985;121(2):207–13.
Bath-Hextall F, Bong J, Perkins W, et al. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705.
Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–30.
Miller SJ, Maloney ME, editors. Cutaneous oncology.Pathophysiology, diagnosis and management. Malden: Blackwell Science. 1998:695–698.
Van Loo E, Mosterd K, Krekels GAM, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–20.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
